Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics
18 oct. 2022 07h15 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia
10 oct. 2022 08h05 HE
|
Silo Pharma, Inc.
Studies of SP-26, the company’s proprietary, time-released ketamine show positive results in reducing neuropathic nerve pain ENGLEWOOD CLIFFS, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Silo...
Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12
06 oct. 2022 08h20 HE
|
Silo Pharma, Inc.
Presentation to feature Company’s novel therapeutic candidates under development in collaboration with leading academic institutions ENGLEWOOD CLIFFS, NJ, Oct. 06, 2022 (GLOBE NEWSWIRE) --...
Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology
03 oct. 2022 09h47 HE
|
Silo Pharma, Inc.
Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine ENGLEWOOD CLIFFS, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the...
Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option
30 sept. 2022 08h30 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...
Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock
27 sept. 2022 09h05 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ , Sept. 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional...
Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq
15 sept. 2022 08h00 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ , Sept. 15, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine
27 juil. 2022 08h15 HE
|
Silo Pharma, Inc.
Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma,...
Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients
12 juil. 2022 11h23 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, N.J, July 12, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announces that its novel liposomes reached a positive...
Silo Pharma Expands License Agreement and Patent Portfolio
23 juin 2022 08h05 HE
|
Silo Pharma, Inc.
Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes Therapeutics Would Target Multiple Diseases Including Auto Immune Disorders ENGLEWOOD CLIFFS, N.J., June ...